Mark Purcell
Stock Analyst at Morgan Stanley
(1.39)
# 3,514
Out of 5,072 analysts
6
Total ratings
66.67%
Success rate
-4.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $50.03 | +15.93% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $130.44 | -12.60% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $48.02 | -8.37% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $93.32 | -8.92% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $48.71 | +146.36% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $50.03
Upside: +15.93%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $130.44
Upside: -12.60%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $48.02
Upside: -8.37%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $93.32
Upside: -8.92%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $48.71
Upside: +146.36%